Heterogeneity in cardiorenal protection by Sodium glucose cotransporter 2 inhibitors in heart failure across the ejection fraction strata: Systematic review and meta-analysis

Figure 2 Meta-analysis of primary composite outcome. A: Gliflozins’ effect on the primary composite outcome across heart failure subtypes; B: Gliflozins’ effect on the composite outcome of ‘cardiovascular deaths or hospitalizations due to heart failure or urgent visits’ across heart failure subtypes. HF: Heart failure; HFpEF: Heart failure with preserved ejection fraction; HFrEF: Heart failure with reduced ejection fraction; nos: Not otherwise specified; N/A: Not available. ^aper 1000 person-years; ^bper 100 person-years.